-
-
-
-
-
-
-
Aprea reports second partial response in cancer drug trial
-
-
-
-
-
-
-
Aprea Therapeutics reports early activity signals for cancer drug APR-1051
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Aprea (APRE)
-
443,299 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

